In The News
Filecoin, founder can’t shake developer’s case over cryptocurrency pay
‘Substantial failure on both sides’: Judge grounds spat between Moccona, Vittoria
Chemist Warehouse, Sigma win ACCC approval for $8.8B merger
Class actions against Ford, Toyota score major win in High Court
Dixon Advisory director reasonably relied on Minters advice, court finds
Slaters HR head says she was fired for reporting systemic underpayments
Fearful of trolling, counsel tapped for Lehrmann wants to stay unnamed
Bid to revive Robodebt class action faces ‘significant hurdles’, says judge
High Court finds curfew, ankle bracelet regime for former detainees unlawful
$405M pelvic mesh settlement distribution can’t ‘drag on’, judge says
Please login to bookmarkClose

ASX-listed generic drug maker Mayne Pharma is facing a possible shareholder class action over disclosures related to US price-fixing allegations against the ASX-listed company.

Subscribe for instant access to all Lawyerly content.

Already a subscriber?
Lost your password?

Contact us to enquire about group subscriptions.
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au